Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.64 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.46 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.39 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.36 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.36 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | LAP3 | P28838 | 2/20 | 0.36 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL348968 | 0.96 | SLC7A5 (0.69) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL27569034 | 0.96 | SLC7A5 (0.69) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL16225151 | 0.93 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL4664449 | 0.93 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL4394541 | 0.93 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL3049775 | 0.93 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL4946381 | 0.93 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL782845 | 0.93 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL5665165 | 0.93 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Serine SCHEMBL3727121 | 0.91 | SLC7A5 (0.46) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050164182-A1 | Nucleoside comprising reporter molecule cleavable by hydrolase such as esterases, phosphatases, peptidases, penicillin amidases, glycosidases, and phosphorylases; limits polymerase activity; sequencing; solid phase synthesis | GE HEALTHCARE UK LIMITED (GB) | 2005-07-28 | — | — | US | claimed |
| JP-2005517646-A | — | — | 2005-06-16 | — | — | JP | claimed |
| EP-1451201-A2 | NUCLEOTIDE ANALOGUES AND THEIR USE FOR NUCLEIC ACID SEQUENCING | Amersham Biosciences UK Limited (GB) | 2004-09-01 | — | — | EP | claimed |
| WO-2003048178-A2 | NUCLEOTIDE ANALOGUES AND THEIR USE FOR NUCLEIC ACID SEQUENCING | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2003-06-12 | — | — | WO | claimed |
| US-20050164182-A1 | Nucleoside comprising reporter molecule cleavable by hydrolase such as esterases, phosphatases, peptidases, penicillin amidases, glycosidases, and phosphorylases; limits polymerase activity; sequencing; solid phase synthesis | GE HEALTHCARE UK LIMITED (GB) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164182-A1 | Nucleoside comprising reporter molecule cleavable by hydrolase such as esterases, phosphatases, peptidases, penicillin amidases, glycosidases, and phosphorylases; limits polymerase activity; sequencing; solid phase synthesis | PNP, PEPD, DNPEP | SLC7A5 2009/4885SLC1A3 2903/4885SLC1A2 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.